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Abstract 
Introduction and objectives. The aim of the present study was to examine the prognostic significance of heart rate and 
its trend in heart transplantation. 
Methods. This observational study enrolled 170 patients who received a bicaval heart transplant between 1995 and 
2005; all were in sinus rhythm. The resting heart rate was determined via electrocardiography at the end of the first 
posttransplant year and annually until the tenth year. Cox analysis was used to evaluate the incidence of adverse 
events with a mean (standard deviation) follow-up of 8.9 (3.1) years. The primary study end point was the composite 
outcome of death or graft dysfunction. 
Results. The resting heart rate at the end of the first posttransplant year was an independent predictor of the primary 
composite end point (hazard ratio = 1.054; 95% confidence interval, 1.028-1.080; P < .001) and was significantly 
associated with total mortality (hazard ratio = 1.058; 95% confidence interval, 1.030-1.087; P < .001) and mortality 
from cardiac causes (hazard ratio = 1.069; 95% confidence interval, 1.026-1.113; P = .001), but not with graft 
dysfunction (hazard ratio = 1.028; 95% confidence interval, 0.989-1.069; P = .161). For patients with a heart rate ≥ 
105 or < 90 bpm vs those with 90-104 bpm, the hazard ratios of the primary end point were 2.233 (95% confidence 
interval, 1.250-3.989; P = .007) and 0.380 (95% confidence interval, 0.161-0.895; P = .027), respectively. Heart rate 
tended to decrease in the first 10 years after transplantation (P = .001). Patients with a net increase in heart rate during 
follow-up showed a higher incidence of adverse events. 
Conclusions. An elevated heart rate is an adverse prognostic marker after heart transplantation. 
Resumen 
Introducción y objetivos. Estudiar la evolución y el significado pronóstico de la frecuencia cardiaca tras el trasplante 
cardiaco. 
Métodos. Estudio observacional de 170 pacientes que recibieron un trasplante cardiaco bicavo entre 1995 y 2005; 
todos estaban en ritmo sinusal. La frecuencia cardiaca en reposo se determinó a partir de electrocardiogramas al final 
del primer año tras el trasplante y anualmente hasta el décimo año. Mediante análisis de Cox, se evaluó la incidencia 
de eventos adversos en un seguimiento medio de 8,9 ± 3,1 años. El evento principal del estudio fue la variable 
combinada muerte o disfunción del injerto. 
Resultados. La frecuencia cardiaca en reposo, medida al final del primer año tras el trasplante, fue un predictor 
independiente del evento combinado principal (hazard ratio = 1,054; intervalo de confianza del 95%, 1,028-1,080; 
p < 0,001). Se observó una asociación estadísticamente significativa con la mortalidad total (hazard ratio = 1,058; 
intervalo de confianza del 95%, 1,030-1,087; p < 0,001) y con la mortalidad por causas cardiacas (hazard ratio = 
1,069; intervalo de confianza del 95%, 1,026-1,113; p = 0,001), pero no con la disfunción del injerto (hazard 
ratio = 1,028; intervalo de confianza del 95%, 0,989-1,069; p = 0,161). Para los pacientes con frecuencia cardiaca ≥ 
105 y < 90 lpm frente a aquellos con 90-104 lpm, las hazard ratio del evento principal fueron, respectivamente, 2,233 
(intervalo de confianza del 95%, 1,250-3,989, p = 0,007) y 0,380 (intervalo de confianza del 95%, 0,161-0,895; 
p = 0,027). Este parámetro presentó una tendencia decreciente en los primeros 10 años del trasplante (p = 0,001). Los 
pacientes con incremento neto de frecuencia cardiaca en el seguimiento mostraron mayor incidencia de eventos 
adversos. 
Conclusiones. La frecuencia cardiaca elevada es un marcador pronóstico adverso tras el trasplante cardiaco. 
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INTRODUCTION 
An elevated heart rate (HRT) is an independent marker of cardiovascular risk.
1
 Heart rate is strongly 
associated with the incidence of cardiovascular events in healthy individuals
2





 and heart failure (HF).
5
 In addition, chronic treatment with heart rate-
reducing agents, such as beta-blockers and ivabradine, improves prognosis in certain subgroups of 




Heart transplantation (HTx) continues to be the alternative therapy of choice in patients with 
refractory HF. For carefully selected candidates, HTx offers excellent long-term survival and quality of 
life.
9,10
 As a result of autonomic denervation, HTx patients have a higher resting HRTthan individuals 
with native hearts.
11
 Although this finding is often considered normal, some studies have indicated that 
HTx recipients with a higher heart rate may have worse survival.
12–14
 In one of these studies,
14
 the 
reduced survival was attributed to higher mortality from graft vascular disease (GVD). However, other 
authors
12
 failed to see differences in the distribution of causes of death according to HRT values. Thus, 




The aim of the present study was to analyze the prognostic significance of HRT in HTx patients, 
particularly focusing on its association with survival, causes of death, and graft function, as well as to 
describe its long-term trend. 
METHODS 
Study Population 
A retrospective analysis was conducted of a historical cohort of adult patients (> 18 years) who 
received an orthotopic HTx in our center between 1995 and 2005. The study included all patients who 
underwent surgery using a bicaval technique and who survived at least 1 year and were at that time in 
sinus rhythm. The following patients were excluded: those with repeat HTx, multiorgan transplantation, 
severe anemia (hemoglobin < 10 g/dL), a pacemaker, or treatment with beta-blockers, diltiazem, 
verapamil, digoxin, amiodarone, or ivabradine. The study protocol was approved by the Comité 
Autonómico de Ética en la Investigación de Galicia. 
Protocol 
Patients were treated according to the local protocol. All patients received induction therapy with 
muromonab-CD3 or basiliximab during the immediate postoperative period. The maintenance 
immunosuppressive regimen comprised various combinations of prednisone, calcineurin inhibitors 
(tacrolimus or cyclosporine), antiproliferative agents (mycophenolate mofetil or azathioprine), and mTOR 
inhibitors (everolimus or sirolimus).  
Endomyocardial biopsies were systematically performed during the first post-HTx year and thereafter 
if there was suspicion of acute rejection. Antidonor antibodies and immunopathological markers of 
humoral rejection were also measured if there were suggestive clinical findings. Coronary angiography 
was initially performed only in patients suspected of having GVD. However, from 2003 onward, this 
procedure was also performed after 1 month and 1, 5, and 10 years after the HTx in asymptomatic 
patients, unless contraindicated. 
Variables 
Study data were retrospectively collected via medical history review. The resting HRT was 
determined from resting electrocardiograms performed in stable patients during regular visits to the 
outpatient service. Baseline HRT was determined at the end of the first post-HTx year and thereafter at 
annual intervals until the tenth post-HTx year. The baseline determination was calculated as the mean of 
all HRT measurements made via electrocardiograms obtained in outpatient visits between the tenth and 
twelfth month (fourth trimester) after the HTx. Updated information on the vital status of all study 
patients was obtained in March 2012. No patients were lost to follow-up. 
 
The primary end point of the study was the composite outcome of all-cause mortality or graft 
dysfunction. Other events analyzed were the 2 individual components of the primary end point and 
cardiovascular mortality. Graft dysfunction was defined as any hospitalization due to clinical HF in the 
presence of a left ventricular ejection fraction (LVEF) < 45%, determined by echocardiography or 
ventriculography, or of restrictive graft physiology, determined by echocardiography or an invasive 
hemodynamic study.
18
 Cardiovascular mortality was defined as that caused by HF, myocardial ischemia, 
or arrhythmia, including those deaths attributable to acute rejection, GVD, or any unexplained sudden 
death. 
 
The causes of death were collected from autopsy reports and death certificates. Patients hospitalized 
due to graft dysfunction underwent a complete diagnostic work-up, including transthoracic 
echocardiography, coronary angiography, a hemodynamic study, and endomyocardial biopsy. A 
diagnosis of GVD was made in the presence of focal coronary stenosis > 50% in a main epicardial vessel 
or diffuse concentric thickening of the entire vessel. Acute cellular rejection was considered the cause of 
graft dysfunction if it was classified as histological grade 2R or higher.
19
 In the absence of other causes, 
humoral rejection was considered to be the cause of graft dysfunction in patients who showed positive 
immunofluorescence for C4d with a pericapillary pattern. 
Statistical Analysis 
Categorical variables are presented as proportions, whereas continuous variables are presented as 
means (standard deviation). A Kolmogorov-Smirnov test was used to study the normality of the HRT 
values. Associations between baseline clinical characteristics and HRT were analyzed using Pearson's 
correlation coefficient for continuous variables, a Student t test for dichotomous qualitative variables, and 
analysis of variance with Bonferroni correction for qualitative variables with 3 or more categories. 
 
Cox multivariate regression was used to determine the prognostic significance of the resting HRT at 
the end of the first post-HTx year. Based on clinical experience and the literature, the following candidate 
variables were selected for this analysis: donor age, recipient age, donor sex, recipient sex, diabetes 
mellitus, baseline heart disease and cytomegalovirus serological status, serum creatinine, and 
immunosuppression type. For each of the studied end points, a multivariate-adjusted model was 
constructed to include all variables whose entry or removal significantly changed the hazard ratio (HR) of 
the variable whose effect was the object of adjustment (HRT at the end of the first post-HTx year). Entry 
of the donor age was forced in all final models due to the correlation observed between this variable and 
heart rate. The variables retained in the final adjusted models were donor age, donor sex, and diabetes 
mellitus (death or graft dysfunction and all-cause mortality); donor age, donor sex, and recipient sex 
(cardiovascular mortality); and donor age (graft dysfunction). 
  
For the analysis of follow-up events, patients were classified into 3 subgroups based on whether their 
HRT at the end of the first post-HTx year was found in the lower quartile, 2 middle quartiles, or upper 
quartile of the study population. Using the multivariate models described above, the adjusted HRs (aHRs) 
and cumulative incidence curves of the study events were calculated in these subgroups, considering as a 
reference category the patients with HRT in the 2 middle quartiles. 
 
The HRT trend in the first 10 years after the HTx was studied using a repeated measures analysis of 
variance with Greenhouse-Geisser correction. In addition, the temporal trend in this parameter was 
estimated in each patient. The trend was considered increasing (a net increase in heart rate) in patients 
with a difference of > 0 between the mean of all annual HRT measurements and the baseline 
determination. Otherwise, the trend was considered decreasing (a net reduction in heart rate). The 
previously constructed multivariate models were used to calculate the aHRs and cumulative incidence 
curves of study events for the subgroups of patients with increasing and decreasing HRT trends during 




Between 1995 and 2005, 393 patients received an orthotopic HTx in our center. Of these, 322 
survived at least 1 year after the intervention. A total of 152 patients were excluded from this study for 
the following reasons: treatment with negative chronotropes (n = 132), simultaneous heart and renal 
transplantation (n = 4), repeat HTx (n = 2), severe anemia (n = 2), and absence of analyzable 
electrocardiograms (n = 12). The study population consisted of the 170 remaining patients. Their baseline 
clinical characteristics are shown in Table 1. 
  
Table 1. Clinical Characteristics of the Patients Included in the Study 
Recipients 
  
 Age, mean (SD), y 52.9 (12.6) 
 Women 34 (20) 
 Baseline heart disease 
  Ischemia 56 (32.9) 
  Dilated 84 (49.4) 
  Other 30 (17.6) 
 Diabetes mellitus 36 (21.2) 
 Hypertension 111 (65.3) 
 Creatinine, mean (SD), mg/dL 1.44 (0.49) 
 Body mass index, mean (SD) 25.6 (5.4) 
Donors 
 Age, mean (SD), y 39.6 (13.3) 
 Women 42 (24.7) 
 Cytomegalovirus serology 
  Recipient + 144 (84.7) 
  Recipient –/donor + 20 (11.8) 
  Recipient –/donor – 6 (3.5) 
Transplantation surgery 
 Urgent transplantation 34 (20) 
 Ischemia time, mean (SD), min 182.1 (81.1) 
 CPB time, mean (SD), min 119.6 (30.6) 
Immunosuppression 
 Muromonab-CD3 86 (50.6) 
 Basiliximab 84 (49.4) 
 Cyclosporin 153 (90) 
 Tacrolimus 16 (9.4) 
 Prednisone 170 (100) 
 Mycophenolate mofetil 134 (78.8) 
 Azathioprine 30 (17.6) 
 Sirolimus or everolimus 7 (4.1) 
  
 
CPB, cardiopulmonary bypass; SD, standard deviation. 
Unless otherwise indicated, values are expressed as No. (%). 
At the end of the first post-HTx year, the resting HRT of the study population had a normal 
distribution (Kolmogorov-Smirnov test, P = .522). The mean HRT was 96.1 (SD, 1.4) bpm, and the first, 
second, third, and fourth quartiles were 55-89, 90-96, 97-104, and 105-132 bpm, respectively. The only 
baseline clinical variable showing a statistically significant correlation with HRT at the end of the first 
post-HTx year was donor age (r = –0.253; P = .001). The correlations between the different baseline 
clinical variables studied and HRT are shown in Tables 1 and 2 of the Supplementary Material. 
Adverse Events 
During a mean follow-up of 8.9 (SD, 3.1) years, 20 patients (11.8%) had graft dysfunction and 47 
(27.6%) died. The composite primary study end point occurred in 55 patients (32.3%). Graft dysfunction 
was attributed to GVD in 10 patients, to humoral rejection in 4, and cellular rejection in 3. No specific 
cause of the graft dysfunction could be identified in the 3 remaining patients. 
  
In addition, 23 deaths (48.9%) were attributed to cardiac causes: refractory HF in 7 patients 
(secondary to GVD in 5 patients and to cellular rejection in 2 patients) and sudden death in 16 patients (5 
of these had a previous diagnosis of GVD). Noncardiovascular mortality was due to neoplasms (n = 13), 
infection (n = 8), liver disease (n = 1), drug abuse (n = 1), and hemorrhage (n = 1). 
Prognostic Value of Heart Rate 
The univariate Cox analysis showed a statistically significant association between a higher resting 
HRT at the end of the first post-HTx year and the incidence of the primary composite end point (crude 
HR = 1.042; 95% confidence interval [95%CI], 1.019-1.065; P < .001). This association continued to be 
significant (aHR = 1.054; 95%CI, 1.028-1.080; P < .001) following the multivariate adjustment (Table 2). 
In addition, a significant association was seen between HRT and the risk of all-cause mortality 
(aHR = 1.058; 95%CI, 1.030-1.087; P = .001), as well as the risk of cardiovascular mortality 
(aHR = 1.069; 95%CI, 1.026-1.113; P < .001). There was no statistically significant association between 
HRT and the risk of graft dysfunction (aHR = 1.028; 95%CI, 0.989-1.069; P = .161). 
Table 2. Clinical Variables Associated with the Primary Composite End Point of Death or Graft Dysfunction: Multivariate Cox 
Proportional Hazards Analysis 
 
HR (95%CI) P aHR (95%CI) P 
     
Heart rate 1.042 (1.019-1.065) < .001 1.054 (1.028-1.080) < .001 
Recipient age 1.017 (0.994-1.042) .149 
  
Recipient sex 0.660 (0.312-1.399) .278 
  
Ischemic heart disease 1.305 (0.999-1.704) .051 
  
Diabetes mellitus 1.543 (0.862-2.765) .145 1.670 (0.925-3.014) .089 
Hypertension 0.794 (0.425-1.480) .467 
  
Creatinine 1.118 (0.643-1.946) .692 
  
Body mass index 1.021 (0.984-1.060) .274 
  
Donor age 1.001 (0.990-1.029) .365 1.028 (1.006-1.050) .011 
Female donor 0.477 (0.233-0.978) .043 0.486 (0.235-1.008) .053 
Ischemia time 1.003 (1-1.007) .049 
  
CPB time 1.009 (1.001-1.017) .030 
  
Urgent heart transplantation 1.229 (0.600-2.515) .573 
  
CMV D -/R + serology 1.307 (0.520-3.284) .569 
  
Tacrolimus use 0.929 (0.334-2.580) .887 
  
Mycophenolate mofetil use 0.832 (0.453-1.526) .552 
  
     
 
95%CI, 95% confidence interval; aHR, adjusted hazard ratio; CMV, cytomegalovirus; CPB, cardiopulmonary bypass; D, donor; 
HR, crude hazard ratio; R, recipient. 
The cumulative incidence curves of each of the study end points in the subgroups of patients with 
HRT in the lower quartile (< 90 bpm), in the 2 middle quartiles (90-104 bpm), and in the upper quartile 
(≥ 105 bpm) are shown in Figure 1. Compared with the middle reference category, the aHRs for the main 
composite end point were 2.233 (95%CI, 1.250-3.989; P = .007) and 0.380 (95CI%, 0.161-0.895; 
P = .027) in patients with heart rates ≥ 105 and < 90 bpm, respectively. The aHRs for the other study end 





Figure 1. Cox multivariate analysis: cumulative incidence curves of end points in 3 resting heart rate categories. 
Bpm, beats per minute; HRT, heart rate. 
Table 3. Multivariate Cox Proportional Hazards Analysis 
 
aHR (95%CI) P 
 
Death or graft dysfunction 
 HRT ≥ 105 bpm 2.233 (1.250-3.989) .007 
 HRT < 90 bpm 0.380 (0.161-0.895) .027 
All-cause mortality 
 HRT ≥ 105 bpm 2.476 (1.324-4.630) .005 
 HRT < 90 bpm 0.392 (0.153-1.004) .051 
Graft dysfunction 
 HRT ≥ 105 bpm 1.677 (0.628-4.477) .302 
 HRT < 90 bpm 0.472 (0.128-1.739) .259 
Cardiovascular mortality 
 HRT ≥ 105 bpm 2.407 (1-5.798) .050 
 HRT < 90 bpm 0.120 (0.015-0.937) .043 
   
 
95%CI, 95% confidence interval; aHR, adjusted hazard ratio; bpm, 
beats per minute; HRT, heart rate. 
aHRs of the study end points in 3 resting heart rate categories at the 
end of the first post-transplant year. Risk estimation was performed 
with respect to the reference category of patients with a heart rate 




Long-term Heart Rate Changes 
During the first 10 years of follow-up after the HTx, the mean HRT of the study population showed a 
linear decreasing trend (P = .001) (Figure 2). Patients showing a net increase in HRT during follow-up 
had a significantly higher incidence of the primary composite end point (aHR = 2.857; 95%CI, 1.514-
5.391; P = .001) than patients with a net decrease in heart rate. The risks of all-cause mortality 
(aHR = 2.104; 95%CI, 1.069-4.142; P = .031), graft dysfunction (aHR = 6.839; 95%CI, 2.371-19.730; 
P < .001), and cardiovascular mortality (aHR = 4.051; 95%CI, 1.536-10.684; P = .005) were also 
significantly higher in patients with a net increase in heart rate. The cumulative incidence curves of end 




Figure 2. Temporal trend in the resting heart rate in 
the first 10 years after transplantation. The points 
represent mean heart rate values of the end of the 
first year and in the subsequent annual follow-ups, 






Figure 3. Multivariate Cox proportional hazards analysis: cumulative incidence curves of end points in patients 
who experienced a net increase or net reduction in heart rate during follow-up. 
DISCUSSION 
The present study supports the prognostic value of HRT in HTx patients. In our series, the presence of 
a higher resting HRT at the end of the first post-HTx year was independently associated with an increased 
cumulative incidence of the composite end point of all-cause mortality and graft dysfunction. This result 
was due to increased overall mortality; however, the tendency toward a higher risk of graft dysfunction 
failed to reach statistical significance, probably due to the small number of events and the low statistical 
power for the individual analysis of these events. Notably, the prognostic significance of HRT was not 
limited to a single measurement, because the temporal tendency of the parameter was shown to be a 
prognostic marker independently of the baseline values. 
 
Heart transplant operations necessitate transection of the autonomic fibers innervating the native heart. 
Due to the lack of parasympathetic stimulation, the HRT of transplanted hearts are largely determined by 
their response to circulating catecholamines.
11
 Compared with healthy controls, HTx recipients show a 
persistent elevation of resting HRT with limited circadian variability and a delayed response to exercise.
11
 
A “normal” HRT remains to be clearly defined, with mean values in different series varying between 85 
and 100 bpm.
12–17
 This apparent variability is due to differences in surgical techniques, donor age, and 
drug treatment, as well as the time since the HTx, because some patients experience a gradual 




At the end of the first post-HTx year, the resting HRT values in our population were normally 
distributed, with mean and median coinciding at 96 bpm and a middle interquartile range of 90 to 104 
bpm. In relation with this reference category, patients with a HRT ≥ 105 bpm showed an increase of more 
than twice the incidence of the primary end point of death or graft dysfunction, whereas this incidence 





 observed significantly lower survival in HTx patients with a resting HRT > 90 bpm than in 
those with a HRT < 90 bpm, whereas Melero-Ferrer et al
13
 reached a similar conclusion using a 100 bpm 
threshold. Measurement of HRT was performed at 1 post-HTx year in 2 of these studies
13,14
 and at 3 




The negative prognostic impact of the elevated HRT values seen in our study is attributable to an 
increased risk of cardiovascular mortality, mainly refractory HF and sudden death. The most frequent 
underlying heart disease in these patients was GVD, which was the cause of death in close to half of the 
patients who died of cardiac causes. However, the absence of systematic coronary angiographies in 
patients who received transplants during the first years of the study hinders a more accurate estimation of 
the impact of GVD on cause of death in our population. In fact, the rate of GVD was likely higher than 
that detected, given the high proportion of unexplained sudden deaths. In the study by Castel et al,
14
 the 
lower survival of HTx recipients with higher HRT values was attributed to an increased mortality from 
GVD. However, Anand et al
12
 failed to see any association between resting HRT and the distribution of 





The reasons for the association between HRT and risk of death remain to be determined in HTx 
patients. In some cases, the high HRT can be attributed to an adaptive reaction
21
 to an underlying adverse 
clinical condition such as hypovolemia, anemia, graft dysfunction, bronchopulmonary disease, infection, 
or neoplasia, so that it should be interpreted as a risk marker rather than a strict risk factor. Nevertheless, 
permanent tachycardia could by itself play a causal role in the development of contractile dysfunction of 
the graft, mediated by myocardial energy depletion.
21
 In other cases, the HRT elevation can reflect a high 
concentration of circulating catecholamines, which increase the risk of hypertension, myocardial 
ischemia, adverse ventricular remodeling, and arrhythmogenesis.
22
 In addition, it must be remembered 
that persistent HRT elevation in patients with a native heart is implicated in the genesis and progression 
of coronary artery disease.
23
 High HRT stimulates the endothelial expression of adhesion molecules and 
cytokines such as interleukin-6 and tumor necrosis factor-alpha,
24
 which can hypothetically promote an 
immunological response against the coronary vessels of the graft. Nevertheless, studies have yet to show 




The natural history of HTx patients includes a gradual reinnervation of the graft with a progressively 
reduced resting HRT and improved response of HRT to exercise.
20,21
 The mean HRT in our population 
gradually fell in the first 10 years after HTx. Notably, the incidence of the primary composite end point 
was significantly higher in patients with a net increase in HRT in this period than in those who 
experienced the expected net decrease. Anand et al
12
 described a similar association between a decreasing 
trend in the resting HRT and a lower long-term rate of mortality. The progressive HRT decrease after 
HTx likely reflects the recovery of effective parasympathetic innervation of the graft. This phenomenon 
counteracts the deleterious effects of chronic adrenergic stimulation and is thus considered important for 
long-term maintenance of the contractile function of the transplanted heart.
21,25
 Nonetheless, 




Prognostic benefit has been seen in HF and coronary disease patients chronically treated with heart 
rate-reducing drugs, such as beta-blockers and ivabradine.
8–10
 However, their efficacy in HTx recipients 
remains unknown. In general, treatment of these patients with beta-blockers is discouraged, because these 
agents can worsen the contractile function of the graft and exercise capacity.
28,29
 A preliminary study 
indicated that diltiazem use during the first post-HTx year could slow the progression of GVD,
30
 but this 
benefit was not subsequently confirmed. Recently, a small study showed that ivabradine is a safe drug, 
well tolerated and effective for reducing HRT in HTx patients in sinus rhythm,
31
 but there are still no 
conclusive data on its potential clinical benefit in this population. 
 
The present study has some limitations. Due to its observational and retrospective design, the study 
could be affected by selection and information biases inherent to this type of research. In addition, despite 
the use of rigorous multivariate adjustment, we are unable to rule out a possible effect of another untested 
confounding factor on the observed association between HRT and adverse events. The absence of 
information on the onset of de novo tachyarrhythmias during follow-up is another limitation, even if it is 
unlikely to significantly impact the observed results because of its low incidence in patients undergoing 
surgery using the bicaval technique.
32
 Finally, the limited context of this single-center study indicates that 
its external relevance cannot be guaranteed and that the findings should be confirmed in larger 
multicenter populations. 
  
Compared with previous studies examining the relationship between HRT and prognosis following 
HTx (all single center and with small sample sizes),
12–14
 the main strengths of this work are its long 
follow-up, the rigorous selection criteria (eg, use of the same surgical technique in all patients, exclusion 
of patients with drugs or comorbidity that could affect heart rate), the analysis of other end points besides 
total mortality (eg, graft dysfunction, cardiovascular mortality), and the description of the temporal trend 
in HRT and its prognostic implication. 
CONCLUSIONS 
The present study confirms the existence of a strong association between higher resting HRT values 
and worse long-term prognosis in HTx patients. This association is largely due to an increased risk of 
cardiovascular mortality, mainly GVD, through sudden death and refractory HF. According to our results, 
the prognosis is particularly adverse for patients with a markedly higher resting HRT (> 105 bpm) at the 
end of the first post-HTx year and those whose HRT tended to increase over time. This study supports the 
introduction of resting HRT as a simple and easily measured marker of risk in the clinical management of 
HTx patients and indicates the need for new studies evaluating the potential clinical benefit of heart rate-
reducing drugs in this population. The confirmation of the favorable long-term prognosis shown by HTx 
patients with a resting HRT < 90 bpm, in line with that observed in previous studies, supports this cutoff 
value as a hypothetical therapeutic target in future intervention studies. 
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